The genetics and clinical management of mitochondrial disease — covering the dual genetic origins (nuclear and mitochondrial DNA), the unique principles of mitochondrial inheritance (heteroplasmy, bottleneck effect, threshold effect), and the major mitochondrial syndromes encountered in neurogenetics.
Tags: Neurogenetics · Advanced
Mitochondria are the primary producers of cellular ATP through oxidative phosphorylation (OXPHOS). They are found in virtually all nucleated cells, and tissues with high metabolic demand — brain, muscle, heart, liver, kidney — are most vulnerable when OXPHOS is impaired. Mitochondrial diseases are clinically and genetically heterogeneous: they can present at any age, affect any organ, and arise from variants in either the mitochondrial genome or nuclear-encoded mitochondrial genes. The overall prevalence is approximately 1/5,000 — making them among the most common inborn errors of metabolism.
Key Points
The human mitochondrial genome is a circular, double-stranded DNA molecule of 16,569 bp, encoding 13 OXPHOS subunit proteins, 22 transfer RNAs, and 2 ribosomal RNAs. The vast majority of mitochondrial proteins (~99%) are encoded by nuclear DNA and imported into mitochondria. Disease can arise from pathogenic variants in either genome, and nuclear gene variants are more common overall.
Key Points
mtDNA exists in hundreds to thousands of copies per cell, and pathogenic mtDNA variants may be present in some but not all copies — a state called heteroplasmy. The proportion of mutant mtDNA determines clinical expression through the threshold effect. The mitochondrial genetic bottleneck during oogenesis explains why heteroplasmy levels can vary dramatically between mother and offspring.
Key Points
Several classic mitochondrial syndromes have been well-characterized with specific mtDNA variants, recognizable clinical phenotypes, and defined diagnostic criteria. Recognition of these syndromes guides targeted genetic testing, prognostication, and management.
Key Points
Diagnosing mitochondrial disease requires integration of clinical phenotype, metabolic testing, neuroimaging, tissue biopsy findings, and molecular genetics. Genetic counseling is highly complex due to heteroplasmy and the dual genetic origins of disease. Management is largely supportive but several therapies have proven benefit.
Key Points
1. A child has bilateral symmetric T2 hyperintensity on MRI involving the putamen, thalami, and periaqueductal gray matter, with elevated plasma lactate. This MRI pattern is most consistent with:
Bilateral symmetric T2 hyperintensity involving the basal ganglia (especially putamen), thalami, and brainstem (periaqueductal gray, dorsal medulla) is the defining MRI pattern of Leigh syndrome (subacute necrotizing encephalopathy). Combined with elevated lactate in a child, this MRI is diagnostic of Leigh syndrome pending molecular confirmation. The lesions reflect energy failure in high-metabolic-demand brain regions. Leigh syndrome is caused by variants in >75 genes and is the most common mitochondrial disease phenotype in childhood.
2. A patient with mitochondrial disease is started on valproate for epilepsy and develops acute liver failure. This serious adverse event is most likely to occur in patients with variants in which gene?
Valproate-induced hepatotoxicity (Alpers-Huttenlocher syndrome) is most strongly associated with biallelic pathogenic variants in POLG (polymerase gamma), the gene encoding the mitochondrial DNA replication enzyme. Valproate inhibits POLG and mitochondrial beta-oxidation, precipitating acute hepatic failure in POLG-deficient patients. Before prescribing valproate for any epileptic encephalopathy, POLG testing should be strongly considered. POLG variants are an absolute contraindication to valproate. This is one of the most clinically critical pharmacogenomic interactions in neurogenetics.
3. A woman with 40% m.3243A>G heteroplasmy in blood wants to know the risk that her children will have mitochondrial disease. Which statement BEST describes the counseling?
All children of a woman with a heteroplasmic mtDNA variant will inherit some copies of the variant (maternal inheritance). However, the mitochondrial bottleneck — a dramatic reduction and re-amplification of mtDNA during oogenesis — means that heteroplasmy levels in offspring can range from very low (<5%) to very high (>95%), regardless of the mother's heteroplasmy. A mother with 40% heteroplasmy may have a child with 2% (asymptomatic) or 90% (severely affected). This unpredictability makes counseling extremely challenging.
4. A 25-year-old woman presents with recurrent stroke-like episodes with posterior-predominant MRI changes that do not respect vascular territories, lactic acidosis, sensorineural hearing loss, and maternal relatives with diabetes and deafness. The most likely diagnosis and causative variant are:
This is a classic MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, Stroke-like Episodes) presentation. The posterior-predominant MRI lesions not respecting vascular territories, lactic acidosis, maternal diabetes + deafness, and sensorineural hearing loss are hallmarks. The m.3243A>G variant in MT-TL1 (encoding mitochondrial tRNA-Leu) accounts for ~80% of MELAS cases. MERRF causes myoclonus + epilepsy (not stroke-like episodes). KSS causes PEO + pigmentary retinopathy. Leigh syndrome is primarily a pediatric disease.
5. On muscle biopsy, 'ragged-red fibers' are found on Gomori trichrome staining. This finding reflects:
Ragged-red fibers on Gomori modified trichrome stain reflect the compensatory proliferation of dysfunctional mitochondria beneath the sarcolemma and between myofibrils. This proliferation is the muscle fiber's attempt to generate more ATP by producing more (albeit dysfunctional) mitochondria. On COX/SDH combined staining, these fibers typically appear blue (SDH-positive, COX-negative in Complex IV disorders) or hyper-reactive. Ragged-red fibers are a hallmark of mitochondrial myopathy, seen in MELAS, MERRF, KSS, and other mtDNA disorders.